📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Krsnaa Diagnostics Allots INR 430 Crore NCDs to Asian Development Bank
Krsnaa Diagnostics has successfully allotted 43,000 Non-Convertible Debentures (NCDs) worth INR 430 crore to the Asian Development Bank (ADB) on a private placement basis. These unlisted, secured NCDs carry a coupon rate of 7.790% per annum with a tenure of seven years. The repayment is structured in 13 equal half-yearly installments starting six months from the allotment date. This significant capital infusion from a prestigious multilateral institution like ADB provides the company with long-term growth capital at a competitive interest rate.
Key Highlights
Allotment of INR 430 crore worth of NCDs to Asian Development Bank (ADB)
Fixed interest rate of 7.790% per annum payable half-yearly
Long-term tenure of 7 years with final maturity on February 23, 2033
Repayment via 13 equal installments commencing 6 months from allotment
NCDs are secured against identified assets of the company
💼 Action for Investors
Investors should view this as a strong validation of the company's business model by a global institution. The long-term funding at a sub-8% rate is favorable for expansion; monitor the deployment of these funds into high-RoE diagnostic projects.
Krsnaa Diagnostics Q3 FY26 Revenue Up 4% to ₹181 Cr; Recovers ₹130 Cr in Pending Dues
Krsnaa Diagnostics reported a modest 4% YoY revenue growth to ₹1,812 million in Q3 FY26, impacted by seasonal factors and strategic operational pauses to recover government receivables. The company successfully recovered over ₹130 crores during the quarter, significantly improving its cash position and working capital discipline. The B2C segment showed strong momentum with an 8x YoY increase in retail revenue, while the company also expanded into tertiary care with its first PPP-based hospital in Pune. Despite margin pressure from expansion costs like the Rajasthan pathology rollout, management remains confident in the long-term scalability of the PPP model.
Key Highlights
Revenue from operations stood at ₹1,812 million, representing a 4% year-on-year growth.
Successfully recovered over ₹130 crores in long-pending government dues, strengthening the cash position.
Retail (B2C) revenue grew 8x year-on-year, indicating successful diversification beyond PPP contracts.
Network expanded to 190 CT/MRI centers and over 4,000 collection centers across 18 states and UTs.
Launched India's first PPP-based cancer and cardiac care hospital in Pune under the Apulki brand.
💼 Action for Investors
Investors should monitor the stabilization of margins as the Rajasthan pathology rollout matures and the B2C segment scales. The significant improvement in cash collections is a positive sign for working capital health, which has historically been a concern for PPP-heavy models.
Krsnaa Diagnostics Q3 FY26 Revenue Up 4%, Retail Business Grows 8x YoY
Krsnaa Diagnostics reported a 9% YoY increase in 9M FY26 revenue to ₹5,802 million, while Q3 FY26 revenue grew 4% to ₹1,812 million. A standout performer was the retail segment, which saw an 8-fold revenue jump to ₹177 million, now contributing 10% to the total group revenue compared to just 1% a year ago. The company maintained steady EBITDA margins at 28% for the nine-month period despite ongoing investments in the Rajasthan pathology project. Expansion remains a key focus with the launch of the first Apulki Healthcare Hospital and a significant increase in diagnostic touchpoints to 3,101.
Key Highlights
9M FY26 Revenue grew 9% YoY to ₹5,802 mn with EBITDA margins improving by 92 bps to 28%.
Retail segment revenue surged ~8x YoY to ₹177 mn, increasing its contribution to total revenue from 1% to 10%.
Network expanded to 190 CT/MRI centres and 4,034 collection centres, maintaining a 75%+ bid win ratio in PPP projects.
Operationalized the first Apulki Healthcare Hospital, a 150-bed PPP facility for cancer and cardiac care in Pune.
Maintains a significant price advantage, offering services at 50-70% lower than market rates while sustaining industry-standard margins.
💼 Action for Investors
Investors should focus on the rapid scaling of the retail business and the successful execution of the Rajasthan project as key growth drivers. The company's ability to maintain 28% EBITDA margins while offering disruptive pricing makes it a strong player in the affordable diagnostics space.
Krsnaa Diagnostics Q3 Revenue Up 4% YoY; Strong Cash Recovery of ₹130 Cr
Krsnaa Diagnostics reported a modest 4% YoY revenue growth to ₹1,812 mn for Q3 FY2026, while PAT declined by 21% YoY to ₹152 mn due to seasonal softness and front-loaded costs for the Rajasthan project. A significant highlight was the recovery of ₹130 crore in cash, primarily from government receivables, which significantly improves working capital efficiency. The company is also diversifying into tertiary care through Apulki Healthcare, launching a 150-bed hospital in Pune. Management expects the Rajasthan Pathology Project to drive significant revenue growth starting next fiscal year.
Key Highlights
Q3 FY26 Revenue grew 4% YoY to ₹1,812 mn, while 9M FY26 Revenue rose 9% to ₹5,802 mn.
PAT for the quarter decreased 21% YoY to ₹152 mn, impacted by seasonal factors and Rajasthan project readiness costs.
Achieved significant cash recovery of over ₹130 crore during Q3, which is ₹100 crore higher YoY.
Launched the first 150-bed PPP-based cancer and cardiac hospital in Pune under Apulki Healthcare.
The Rajasthan Pathology Project is on track with meaningful revenue contribution expected from FY2027.
💼 Action for Investors
Investors should monitor the execution of the Rajasthan project and the ramp-up of the new Apulki hospital venture as these are key growth drivers. The strong cash recovery addresses historical concerns regarding government receivables, making the long-term investment case more robust despite short-term margin pressure.
Krsnaa Diagnostics Q3 FY26 PAT Drops 23.6% YoY to ₹164.9M; Revenue Down 3.5%
Krsnaa Diagnostics reported a weak performance for Q3 FY26, with standalone revenue declining 3.5% YoY to ₹1,594.32 million. Net profit saw a significant drop of 23.6% YoY, falling to ₹164.92 million from ₹216.00 million in the previous year's corresponding quarter. On a sequential basis, the performance was even softer, with revenue and PAT down 12.8% and 29% respectively compared to Q2 FY26. Furthermore, the company is currently contesting a substantial Income Tax demand of ₹513.86 million across multiple assessment years.
Key Highlights
Standalone Revenue from operations fell 3.5% YoY to ₹1,594.32 million in Q3 FY26.
Net Profit (PAT) declined 23.6% YoY to ₹164.92 million from ₹216.00 million in Q3 FY25.
9M FY26 revenue grew marginally by 2.1% YoY to ₹5,179.29 million, while 9M PAT fell 4% to ₹592.93 million.
The company is contesting an Income Tax demand of ₹513.86 million and has paid ₹102.77 million under protest.
Basic EPS for the quarter decreased to ₹5.08 from ₹6.69 in the same period last year.
💼 Action for Investors
The results indicate a slowdown in growth and margin pressure which may weigh on the stock price in the short term. Investors should closely monitor management's explanation for the revenue dip and the progress of the ongoing tax litigation.
Krsnaa Diagnostics Q3 PAT Falls 23.6% YoY to ₹164.9 Mn; Revenue Down 3.5%
Krsnaa Diagnostics reported a weak set of standalone results for Q3 FY2026, with revenue declining 3.5% YoY to ₹1,594.32 million. Profit After Tax (PAT) saw a sharp decline of 23.6% YoY, falling to ₹164.92 million from ₹216.00 million in the previous year. On a sequential basis, the performance was even more subdued, with revenue and PAT dropping 12.8% and 29.0% respectively compared to Q2 FY2026. Furthermore, the company is currently litigating an Income Tax demand of ₹513.86 million across multiple assessment years.
Key Highlights
Standalone Revenue from operations decreased by 3.5% YoY to ₹1,594.32 million in Q3 FY26.
Standalone Profit After Tax (PAT) dropped significantly by 23.6% YoY to ₹164.92 million.
Total expenses for the quarter stood at ₹1,420.05 million, leading to a contraction in profit margins compared to the previous year.
The company is contesting an Income Tax demand of ₹513.86 million and has paid ₹102.77 million under protest.
For the nine-month period ended Dec 31, 2025, revenue grew marginally by 2.1% YoY while PAT declined by 4%.
💼 Action for Investors
Investors should exercise caution as the company shows signs of growth stagnation and margin pressure both on a YoY and QoQ basis. The ongoing tax dispute involving over ₹500 million remains a key monitorable risk factor.
Krsnaa Diagnostics CFO Pawan Daga Resigns After 5-Year Tenure
Krsnaa Diagnostics Limited has announced the resignation of Mr. Pawan Daga from the position of Chief Financial Officer, effective January 19, 2026. Mr. Daga served the company for five years, a period during which the management credits him for contributing to the firm's growth. The resignation is attributed to personal and professional priorities. The company must now identify a successor to lead its financial operations and maintain investor confidence.
Key Highlights
Mr. Pawan Daga resigns as Chief Financial Officer (CFO) effective January 19, 2026
The outgoing CFO completed a tenure of 5 years with the company
Resignation cited as being due to personal and professional priorities
Announcement made on January 15, 2026, providing a very short 4-day transition period
💼 Action for Investors
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure leadership continuity. The short notice period between the announcement and the exit date is a point for cautious observation.
Krsnaa Diagnostics to issue NCDs worth ₹430 crore
Krsnaa Diagnostics Limited's board approved the issuance of unlisted, secured, redeemable, transferable Non-Convertible Debentures (NCDs) for up to ₹430 crore via private placement. The company plans to issue 43,000 NCDs with a face value of ₹1,00,000 each. These NCDs have a tenure of 7 years from the allotment date and will be redeemed in 13 equal installments starting 6 months from allotment. The interest and principal will be payable on a half-yearly basis.
Key Highlights
Issuance of Unlisted, Secured, Redeemable NCDs for up to ₹430 crore
43,000 NCDs with a face value of ₹1,00,000 each
Tenure of 7 years from the deemed date of allotment
Redemption in 13 equal installments commencing from 6 months from the allotment date
💼 Action for Investors
Investors should monitor the terms of the NCD issuance and its impact on the company's debt levels. Review the company's future announcements regarding the allotment details and the specific assets charged as security.
Krsnaa Diagnostics to Issue NCDs up to ₹430 Crore
Krsnaa Diagnostics Limited's board approved the issuance of unlisted, secured, redeemable, and transferable Non-Convertible Debentures (NCDs) for up to ₹430 crores via private placement. The company will issue 43,000 NCDs with a face value of ₹1,00,000 each. These NCDs have a tenure of 7 years from the allotment date. The principal will be redeemed in thirteen equal installments commencing 6 months from the allotment date, with interest and principal payable on a half-yearly basis.
Key Highlights
Issuance of Unlisted, Secured NCDs up to ₹430 crore
43,000 NCDs to be issued with a face value of ₹1,00,000 each
NCD tenure of 7 years from the deemed date of allotment
Redemption in 13 equal installments starting 6 months from allotment
Interest and principal payable on a half-yearly basis
💼 Action for Investors
Investors should monitor the terms of the NCD issuance and its impact on the company's debt levels. Keep an eye on the interest rates and repayment schedule for these NCDs.